Hiraga et al (2001) have demonstrated that a selective caspase-3 inhibitor is capable of blocking ibandronate-induced DNA fragmentation in MDA-MB-231 breast cancer cells and we have similarly found that caspase-3 inhibition significantly protects against ZOL-induced loss of viability in these cells. This evidence concerns the gene CASP3 and breast cancer.